

Note

Comparison of Uptake between PureSorb-Q™40 and Regular Hydrophobic Coenzyme Q₁₀ in Rats and Humans after Single Oral Intake

Kazuki NUKUI¹, Toshihiko YAMAGISHI¹, Hiromi MIYAWAKI²,
Aikkarach KETTAWAN³, Tadashi OKAMOTO³ and Kiyoshi SATO¹

¹Nisshin Pharma Inc., 25, Kanda-Nishiki-cho 1-chome, Chiyoda-ku, Tokyo 101-8441, Japan

²Miyawaki Orthopedic Clinic, 3-1-6, Ariake-cho, Eniwa Hokkaido 061-1431, Japan

³Department of Health Sciences and Social Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, 518, Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan

(Received October 12, 2006)

Summary Coenzyme Q₁₀ (CoQ₁₀) is a lipid-soluble antioxidant and essential component of the mitochondrial electron transfer system in the body, and is in wide use as a functional food material and cosmetic raw material. However, as CoQ₁₀ is extremely lipid-soluble, absorption by the body is not easy. In general, people use soft-gel capsules in which CoQ₁₀ is suspended in oil, and take these capsules with food. PureSorb-Q™40 (P40) was developed to improve CoQ₁₀ processability and absorption when taken without food, and the present study compared the effects of food on absorption between P40 and conventional lipid-soluble CoQ₁₀ in rats and humans. The results of a rat study showed higher uptake when P40 was administered in the fasting state or with food compared to lipid-soluble CoQ₁₀. The results of a human study showed that uptake was favorable when P40 was administered in the fasting state, and even when administered postprandially, a significant difference was noted in uptake rate up to 6 h after intake and uptake volume up to 8 h after intake when compared to lipid-soluble CoQ₁₀. These results show that any CoQ₁₀ product using P40 can be quickly and reliably absorbed by the body regardless of dosage form or intake time.

Key Words coenzyme Q₁₀, water-soluble, PureSorb-Q™40, uptake

Coenzyme Q₁₀ (CoQ₁₀) is a lipid-soluble substance that plays important roles in the body as an essential factor in the mitochondrial electron transfer system. This biofactor is directly involved in the energy production system of the body (1, 2). CoQ₁₀ was first chemically synthesized in 1958 (3), and has been used since 1974 as an effective agent for improving symptoms associated with congestive heart failure. At present, CoQ₁₀ has been closely examined as a functional food material and cosmetic raw material in and outside of Japan, and because of its excellent safety record, CoQ₁₀ is beginning to gain wide use (4–6). CoQ₁₀ is biosynthesized not only by mitochondria, but also by the microsomal-Golgi system, and thus does not fit the definition of a vitamin (7). In the tissues of many animals, including humans, CoQ₁₀ exists mostly as reduced CoQ₁₀, not oxidized CoQ₁₀. Therefore, CoQ₁₀ has the potent antioxidant action in the body (8, 9). This highly lipid-soluble substance is not easily absorbed by body. Even when taken with food, the absorption rate is about 3% (10). Furthermore, the high lipid solubility means that use in food products is limited. PureSorb-Q™40 (water-soluble type powder. CoQ₁₀ content is 40 w/w%) is a product that was developed to improve processability and absorption in the fasting state while focusing on

safety.

To ascertain the effects of food on the absorption of PureSorb-Q™40, the present study compared serum CoQ₁₀ levels following oral intake of CoQ₁₀ between PureSorb-Q™40 tablets and commercially available lipid-soluble CoQ₁₀ soft-gel capsules.

Materials and Methods

Materials. Male Sprague-Dawley rats (6- to 7-wk-old; body weight: 190–230 g) were purchased from Japan SLC Inc. (Shizuoka, Japan). The PureSorb-Q™40 (Water-soluble type CoQ₁₀ powder. CoQ₁₀ content is 40 w/w%, hereafter P40) developed by Nisshin Pharma Inc. (Tokyo, Japan) was used. In a human oral intake study, P40 tablets, made by Nisshin Pharma Inc., and commercially available lipid-soluble CoQ₁₀ (Q10 oil) soft-gel capsules (30 mg of CoQ₁₀ per capsule) were used. Each P40 tablet weighed 300 mg and contained 30 mg of CoQ₁₀, and other ingredients included starch, reduced maltose, agar, dextrin, cellulose, sucrose ester, glycerin and fine silicon dioxide.

Subjects. Subjects in the human study comprised 20 healthy male volunteers at Miyawaki Orthopedics Hospital (Eniwa, Hokkaido). Mean age was 23.3 y (range, 20–40 y) and mean BMI was 21.2 kg/m² (range, 18–26 kg/m²).

Rat single-dose study. Rats were randomly divided

into the following 4 groups based on body weight: control group ($n=4$, food+water); prandial P40 group ($n=12$, ad libitum access to food and P40 administration); fasting P40 group (overnight fasting (12 h from 20:00 to 08:00 the next morning) and P40 administration); prandial Q10 oil group (ad libitum access to food and Q10 oil administration); and fasting Q10 oil group (overnight fasting (12 h from 20:00 to 08:00 the next morning) and Q10 oil administration). P40 was directly administered to the stomach using an oral tube by dissolving CoQ₁₀ at 3.33 mg/kg body weight (for humans, 200 mg/60 kg body weight). Q10 oil was administered as follows: A commercially available soft-gel capsule was cut using scissors to remove the contents. Water was added, and the resulting solution was warmed for 10 min in a 50°C water bath, then subjected to ultrasonication to prepare a homogenized solution. Intake volume and methods for Q10 oil were the same as those for P40. After CoQ₁₀ administration, no food was given to any group, but the rats had ad libitum access to water. At 6, 10 and 24 h after administration, a blood sample was collected for measuring serum CoQ₁₀ by killing the rats under anesthesia. Rats were fed using Lab MR Stock (Japan SLC).

Human single-dose study. The study was conducted on consenting volunteers under the supervision of the chief investigator and collaborators in accordance with the Declaration of Helsinki, with approval from the Investigational Review Board (Miyawaki Orthopedic Clinic IRB). Screened subjects were randomly divided into 2 groups: fasting group ($n=10$); and postprandial group ($n=10$). In each group, P40 and Q10 oil were administered in a crossover fashion. In other words, a single oral dose 2-group 2-period crossover study was conducted. In the single-dose study, either 2 P40 tablets or 2 Q10 oil capsules (60 mg CoQ₁₀) were administered with food or in the fasting state. Fasting-state subjects were instructed to fast for 12 h, and were then orally administered CoQ₁₀ with 200 mL of water. Conversely, postprandial subjects were orally administered CoQ₁₀ immediately after breakfast with 200 mL of water. In both groups, subjects ate the same lunch 4.5 h after CoQ₁₀ intake. When taking CoQ₁₀ with food, a typical Japanese breakfast was served (600–700 kcal, protein : fat : carbohydrate (PFC) ratio, 15 : 25 : 60) to minimize the effects of dietary differences on CoQ₁₀ absorption. Physical tests, clinical tests (hematological and blood biochemical tests) and doctor interviews were performed before taking CoQ₁₀ and after collecting the final blood sample. Blood samples were collected before CoQ₁₀ intake and 2, 4, 6, 8, 12 and 24 h after intake to measure serum CoQ₁₀ levels.

Measurement of serum CoQ₁₀ levels. Rat serum CoQ₁₀ levels were measured by HPLC using an electrochemical detector according to the methods of Okamoto et al. (11). With each human blood sample, 2 mL of blood was centrifuged at 800×*g* for 10 min, and the resulting serum was subjected to the above-mentioned methods to quantify reduced and total CoQ levels.

Data analysis. In the rat single-dose study, basic sta-

tistics (mean and SD) were calculated for each group, and numerical data were expressed as mean±SE. Uptake rate was calculated based on the slope of serum CoQ₁₀ level at 6 h after intake. Unpaired *t*-tests were used to compare serum CoQ₁₀ levels at 6 h after intake and uptake rate among different groups. In the human single-dose study, basic statistics (mean±SD) were calculated for fasting and postprandial groups, and numerical data were expressed as mean±SE. An unpaired *t*-test was used to compare uptake rate at 6 h after intake and area under the blood drug concentration-time curve for up to 8 h after intake (ΔAUC) between the fasting and postprandial groups, and paired *t*-tests were used to compare P40 and Q10 oil intake within each group. Values of $p<0.05$ were considered statistically significant.

Results

Rat serum CoQ₁₀ levels following CoQ₁₀ intake

Figure 1 shows changes in serum CoQ₁₀ levels up to 24 h after oral administration of P40 or Q10 oil.

Following fasting administration, serum CoQ₁₀ levels peaked 6 h after intake for the P40 group at $0.208 \pm 0.014 \mu\text{g/mL}$, but, for the Q10 oil group, no serum CoQ₁₀ was observed at 6, 10 or 24 h after intake. Following prandial administration, serum CoQ₁₀ levels peaked 6 h after intake for the P40 group at $0.270 \pm 0.044 \mu\text{g/mL}$, but for the Q10 oil group serum CoQ₁₀ levels peaked at 10 h after intake, at $0.183 \pm 0.017 \mu\text{g/mL}$, which is comparable to serum CoQ₁₀ levels at 10 h after intake for the P40 group ($0.175 \pm 0.010 \mu\text{g/mL}$). As shown in Table 1, on the other hand, the endogenous CoQ₉ levels were not changed after oral administration of either P40 or Q10 oil.

CoQ₁₀ uptake rates at 6 h after intake were compared among the groups. CoQ₁₀ uptake rate for the prandial P40 group ($0.031 \pm 0.008 \mu\text{g/mL/h}$) was 4.4-times greater than that for the prandial Q10 oil group ($0.007 \pm 0.002 \mu\text{g/mL/h}$) ($p<0.05$). In addition, CoQ₁₀ uptake rate for the fasting Q10 oil group was zero, com-




Fig. 1. Changes in serum coenzyme Q₁₀ concentrations in rats after single oral intake of 3.33 mg/kg. Values represent mean ±SE ($n=4$). * $p<0.05$ versus Q10 oil intake (Feed). ** $p<0.01$ versus Q10 oil intake (Fasting). ■, Feed+P40; ▲, Fasting+P40; □, Feed+Q10 oil; △, Fasting+Q10 oil.

Table 1. Changes in serum coenzyme Q₉ concentration in rats after single oral intake of 3.33mg/kg.

	6 h after the start of intake	10 h after the start of intake	24 h after the start of intake
Fasting+P40	0.353±0.030	0.368±0.025	0.390±0.025
Feed+P40	0.370±0.015	0.380±0.032	0.368±0.011
Fasting+Q10 oil	0.360±0.032	0.370±0.018	0.390±0.026
Feed+Q10 oil	0.353±0.011	0.370±0.021	0.378±0.040

Serum coenzyme Q₉ concentration of control group is 0.373±0.011 µg/mL (n=4).

Values represent mean±SE (n=4).

Unit is µg/mL.




Fig. 2. Changes in serum coenzyme Q₁₀ concentrations in humans after single oral intake of 60 mg. Values represent mean ±SE (n=10). ■, P40 (After meals); ▲, P40 (Fasting); □, Q10 oil (After meals); △, Q10 oil (Fasting).




Fig. 3. Comparison of ΔAUC_{0-8} between fasting and after-meals groups in humans. Values represent mean ±SE (n=10). * $p < 0.01$ versus Fasting (P40). ** $p < 0.01$ versus Q10 oil (After meals)

pared to 0.021 ± 0.003 µg/mL/h for the fasting P40 group.

Human serum CoQ₁₀ levels following CoQ₁₀ intake (Figs. 2, 3)

The difference in uptake rate between P40 and Q10 oil in rats was compared in the human study. Figure 2 shows changes in serum CoQ₁₀ levels for 24 h after P40 and Q10 oil intake in humans (increase level: Δ).

Unlike in rats, serum CoQ₁₀ levels peaked at 6 h after intake for fasting P40, postprandial P40 and fasting Q10 oil groups, and as with rats, serum CoQ₁₀ levels quickly increased for the postprandial P40 group. Uptake rate up to 6 h after intake for the fasting P40 group was 0.048 ± 0.011 µg/mL/h, and tended to be faster than that for the fasting Q10 oil group (0.018 ± 0.006 µg/mL/h) or postprandial Q10 oil group (0.026 ± 0.008 µg/mL/h), but no significant differences were identified. In addition, uptake rate up to 6 h after intake for the postprandial P40 group (0.065 ± 0.015 µg/mL/h) was 2.6-fold faster than that for the postprandial Q10 oil group ($p < 0.05$).

To confirm the uptake volume of orally ingested exogenous CoQ₁₀, ΔAUC for 8 h after intake was calculated (Fig. 3). The ΔAUC was 0.828 ± 0.211 µg·h/mL for the fasting P40 group, 2.9-fold higher than for the fasting Q10 oil group (0.288 ± 0.109 µg·h/mL), but no significant differences were identified.

The ΔAUC for the postprandial P40 group was 1.869 ± 0.267 µg·h/mL, 2.3-fold greater than that for the fasting P40 group ($p < 0.01$) and 3.4-fold greater than that for the postprandial Q10 oil group ($p < 0.01$).

In the present study, subjective symptoms, objective

symptoms, physiological test findings and clinical laboratory test findings did not indicate any undesirable symptoms resulting from consumption of the investigational products.

Discussion

Exogenous CoQ₁₀, such as dietary CoQ₁₀, is absorbed by epithelial cells in the small intestine and transported via the lymphatic system to the liver, where most CoQ₁₀ stays. CoQ₁₀ absorption and its metabolic pathway are believed to be broadly similar in rats and humans (12). Exogenous and endogenous CoQ₁₀ in the liver is bound to very low density lipoprotein (VLDL) and then secreted into the blood (13). The serum of healthy adults contains about 1 µM of CoQ₁₀, and most CoQ₁₀ exists as reduced CoQ₁₀ in the lipoprotein fraction (14). Serum samples are often used to measure the absorption of exogenous CoQ₁₀ or CoQ sufficiency in the body. However, marked differences have been seen in increased serum CoQ₁₀ levels due to intake of exogenous CoQ₁₀. This may be attributable to individual differences and dietary oil contents, and these factors have been shown to markedly affect serum CoQ₁₀ levels (15). To alleviate the effects of diet on CoQ₁₀ absorption, PureSorb-Q™40 was developed, and the present study investigated CoQ₁₀ uptake in rats and humans. The present results clarified that, for the administration of P40, the effects of food intake were small and CoQ₁₀ was absorbed promptly even when administered in a fasting state. CoQ₁₀ absorption is improved by postprandial P40 intake compared to postprandial lipid-soluble CoQ₁₀ intake. The results of each study are described in

the following sections.

In rats, CoQ₉ is the predominant homologue, and CoQ₁₀ accounts for its several to a dozens of percent (11). CoQ₉ and CoQ₁₀ are widely distributed in the spleen, kidney, heart, liver and plasma. In the liver and plasma, the ratio of reduced CoQ to total CoQ (reduced and oxidized CoQ) is 70–80%, compared to 30% in other tissues (16). The present results did not show any marked differences in serum CoQ₉ levels following oral intake of P40 or Q10 oil, and the ratio of reduced CoQ for CoQ₉ and CoQ₁₀ was 70–80%. This indicates that exogenous CoQ₁₀ intake does not affect the ratio of reduced CoQ in the body. Furthermore, for the fasting Q10 oil group, little chronological change in serum CoQ₁₀ levels was observed, suggesting that in rats, lipid-soluble CoQ₁₀ is not absorbed if not consumed with food. Conversely, under the same conditions, the P40 group displayed a favorable uptake rate of CoQ₁₀, and P40 improved absorption of CoQ₁₀ in the fasting state, while CoQ₁₀ uptake was higher for postprandial P40 than for postprandial lipid-soluble CoQ₁₀.

In the human study, uptake rate for the fasting P40 group was almost the same as for the postprandial Q10 oil group. This means that P40 improves the uptake rate for the fasting state. Hence, although most currently available CoQ₁₀ supplements need to be taken with food, P40 does not, and P40 sufficiently increases serum CoQ₁₀ levels whether taken in the fasting state or with food. Serum CoQ₁₀ levels for the postprandial P40 group were higher than those for the postprandial Q10 oil group, and as with rats, this was attributed to the fact that the uptake rate for the postprandial P40 group 6 h after intake was 2.6-fold faster compared to the postprandial Q10 oil group.

In the present study, the second peak in serum CoQ₁₀ levels was seen at 12 h after intake for the Q10 oil group (Fig. 2). This was attributed to enterohepatic circulation of exogenous CoQ₁₀ uptake by the small intestine, followed by secretion into plasma together with endogenous CoQ₁₀ synthesized in the liver. In a study where deuterium-labeled CoQ₁₀ was administered to humans, serum CoQ₁₀ levels peaked at 6 h after intake, but a second peak was seen 24 h after intake (12), suggesting a similar mechanism was at work for the second peak observed in the present study. For the prandial Q10 oil group in rats, however, the second peak in serum CoQ₁₀ levels was not observed. The difference of the peak between humans and rats might be affected by the collecting interval of blood samples and/or the lunch intake in humans.

When improving the absorption of minimally soluble drugs, reducing particle size is a common technique. P40 is a water-soluble powder with a mean particle size of about 0.19 μm during water dispersion, and was designed so that easy emulsification could occur with bile acid in the intestinal tract, followed by rapid absorption by the intestinal mucosal layer. The tablets used in the present human single-dose study disintegrate within 20 min of oral administration, and changes in serum CoQ₁₀ levels were comparable to the results of a

rat study where powdered P40 was orally administered, suggesting that regardless of dosage form, the particle design of P40 is maintained in the small intestine following oral consumption. These findings clarify that compared to lipid-soluble CoQ₁₀, P40 is quickly and reliably absorbed by the body when consumed in the fasting state or with food. P40 may thus represent a CoQ₁₀ product that is quickly and reliably absorbed by the body regardless of dosage form or intake time.

REFERENCES

- 1) Kishi T. 2001. The role of coenzyme Q in the mitochondrial respiratory chain. *Vitamins* **75**: 263–271.
- 2) Lenaz GA, Baracca C, Bovina M, Cavazzoni M, D'Aurelio S, Di Bernardo R, Fato G, Formiggini ML, Genova AM, Ghelli MM, Pich F, Pallotti GP, Castelli, Ventura B. 2000. Mitochondrial bioenergetics in health and disease. *Recent Res Develop Bioenerg* **1**: 63–101.
- 3) Shunk CH, Linn BO, Wong EL, Wittreigh PE, Robinson PE, Folkers K. 1958. Coenzyme Q II. *J Am Chem Soc* **80**: 47523.
- 4) Ikematsu H, Nakamura K, Harashima S, Fujii K, Fukutomi N. 2006. Safety assessment of coenzyme Q₁₀ (Kaneka Q₁₀) in healthy subjects: A double-blind, randomized, placebo-controlled trial. *Regul Toxicol Pharmacol* **44**: 212–218.
- 5) Ikeda K, Suzuki Y, Yoshimura I. 2005. Mutagenicity of coenzyme Q₁₀. *J Nutr Sci Vitaminol* **51**: 45–47.
- 6) Hatakeyama S, Kawase S, Yoshimura I. 2006. Comparative oral toxicity of coenzyme Q₁₀ and its (2Z)-isomer in rat: Single and four-week repeated dose toxicity studies. *J Nutr Sci Vitaminol* **52**: 9–20.
- 7) Nakamura T. 2001. (2) Seigousei to taisha. *Vitamins* **75**: 273–278.
- 8) Turunen M, Olsson J, Dallner G. 2004. Metabolism and function of coenzyme Q. *Biochim Biophys Acta* **1660**: 171–199.
- 9) Frei B, Kim MC, Ames BN. 1990. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. *Proc Natl Acad Sci USA* **87**: 4879–4883.
- 10) Weber C, Bysted A, Holmer G. 1997. Coenzyme Q10 in the diet-daily intake and relative bioavailability. *Molec Aspects Med* **18S**: s251–s254.
- 11) Okamoto T, Fukunaga Y, Ida Y, Kishi T. 1988. Determination of reduced and total ubiquinones in biological materials by liquid chromatography with electrochemical detection. *J Chromatogr* **430**: 11–19.
- 12) Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N. 1986. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. *Int J Clin Pharmacol Ther Toxicol* **24**: 536–541.
- 13) Kalén A, Morrling B, Appelkvist EL, Dallner G. 1987. Ubiquinone biosynthesis by the microsomal fraction from rat liver. *Biochim Biophys Acta* **926**: 70–78.
- 14) Zhang Y, Turunen M, Appelkvist E. 1996. Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of α -tocopherol into rat organs and cells. *J Nutr* **126**: 2089–2097.
- 15) Langsjoen H, Langsjoen P, Willis R. 1994. Usefulness of coenzyme Q10 in clinical cardiology: A long-term study. *Molec Aspects Med* **15S**: s165–s175.
- 16) Takahashi T, Okamoto T, Mori K, Sayo H, Kishi T. 1993. Distribution of ubiquinol homologues in rat tissues and subcellular fractions. *Lipids* **28**: 803–809.